SOCRA CCRP — Certified Clinical Research Professional — Questions and Answers

Question 1: What does 21CFR54 deal with?

Financial disclosure of clinical investigators (Correct answer)
IRB regulations
Exemptions of Informed Consent for emergency use
Protection of human subjects: prisoners

Correct answer: Financial disclosure of clinical investigators

21 CFR Part 54 deals with 'Financial Disclosure by Clinical Investigators.' This regulation requires sponsors to collect and report information about financial interests of clinical investigators that could affect the reliability of study data. Its purpose is to ensure the integrity of clinical trial results by identifying and mitigating potential biases arising from financial relationships.

Question 2: What is 21 CFR 50.27?

Irb review of research
Documentation of informed consent (Correct answer)
Hhs - protection of human health subjects
Exception from general requirements

Correct answer: Documentation of informed consent

21 CFR 50.27 specifically details the 'Documentation of Informed Consent' requirements. This section outlines how informed consent must be recorded, typically through a written consent form signed and dated by the subject or their legally authorized representative. It ensures that there is a clear record that the informed consent process was properly conducted and documented.

Question 3: What happens when an FDA inspection results in a Form 483?

Drug is approved
The FDA issues observations of conditions that may constitute violations requiring corrective actions (Correct answer)
Site is closed immediately
No action required

Correct answer: The FDA issues observations of conditions that may constitute violations requiring corrective actions

Form 483 lists inspectional observations of conditions that may constitute violations. Sites should respond within 15 business days.

Question 4: Which of the following is an example of undue influence in the consent process?

Providing a subject with a bus pass to cover travel costs
Explaining all risks clearly in simple language
A physician-investigator implying poorer care will result if the patient refuses to enroll (Correct answer)
Offering fair market value compensation for study participation

Correct answer: A physician-investigator implying poorer care will result if the patient refuses to enroll

Undue influence occurs when a person in authority implies negative consequences for non-participation, compromising truly voluntary consent.

Question 5: According to 21 CFR 312.32, what is the maximum timeframe within which a sponsor must report an unexpected fatal or life-threatening suspected adverse reaction to the FDA?

24 hours after becoming aware of the event.
15 calendar days after the sponsor's initial receipt of the information.
7 calendar days after the sponsor's initial receipt of the information. (Correct answer)
10 working days after the site reports the event to the sponsor.

Correct answer: 7 calendar days after the sponsor's initial receipt of the information.

21 CFR 312.32(c)(2) mandates that sponsors must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible, but no later than 7 calendar days after first receiving the information. The 15-day timeframe applies to serious and unexpected suspected adverse reactions that are not fatal or life-threatening.

Question 6: During a monitoring visit, a CRA discovers that source documents for three subjects cannot be located. What is the most appropriate immediate action?

Inform the FDA directly without notifying the site PI
Create new source documents based on the CRF data to replace the missing records
Document the finding in the monitoring report and work with the site to investigate and resolve the missing records (Correct answer)
Remove those subjects from the trial database immediately

Correct answer: Document the finding in the monitoring report and work with the site to investigate and resolve the missing records

The monitor must document the missing records, report to the site team, and follow up to determine if records can be located or if a protocol deviation must be reported.

Question 7: A clinical investigator is participating in a pivotal Phase III drug trial intended to support a marketing application. According to 21 CFR Part 54, the investigator must provide the sponsor with sufficient financial information. The investigator must promptly update this information if any relevant changes occur during the investigation and for what period of time following the completion of the study?

There is no requirement to update after study completion.
For 2 years following study completion.
For 6 months following study completion.
For 1 year following study completion. (Correct answer)

Correct answer: For 1 year following study completion.

According to 21 CFR 54.4(b), the investigator is required to provide the sponsor with accurate financial information and must 'promptly update this information if any relevant changes occur in the course of the investigation or for 1 year following completion of the study.' This ensures that the sponsor has current information when submitting the marketing application to the FDA.

Question 8: Which of the following is the proper way to make a correction to a CRF?

Completely blacken the incorrect entry and then enter the correct information
Back date the corrected entry with the date of the original entry
Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change (Correct answer)
Initial using the initials of the sponsor's representative who reviewed the change

Correct answer: Add the initials of the person making the change, the date of the change, and , if necessary, a brief explanation of the change

When making corrections to a Case Report Form (CRF), the proper procedure is to draw a single line through the incorrect entry, ensuring the original entry remains legible. Then, the correct information should be written next to it, followed by the initials of the person making the change, the date of the change, and a brief explanation if necessary. This method maintains an audit trail and ensures data integrity.

Question 9: What is the FDA form 3455?

Certification - Disclosure of Conflict of Interest
Certification - Financial Interests and Arrangements of Clinical Investigators
Disclosure - Financial Interests and Agreements of Clinical Investigators (Correct answer)
Declaration of Conflict of Interest

Correct answer: Disclosure - Financial Interests and Agreements of Clinical Investigators

FDA Form 3455 is specifically titled 'Disclosure - Financial Interests and Agreements of Clinical Investigators.' This form is used by clinical investigators to disclose any financial interests or arrangements they or their immediate family members have with the sponsor of a covered clinical study. This disclosure is crucial for identifying and managing potential conflicts of interest that could bias study results.

Question 10: What is the maximum period of approval an IRB may grant for a clinical study under 21 CFR Part 56?

2 years
1 year (Correct answer)
Until the study ends
6 months

Correct answer: 1 year

Per 21 CFR 56.109(f), IRB approval must be renewed at intervals not exceeding one year; continuing review must occur at least annually.

Question 11: Which of the following protocol deviations would MOST likely be classified as a major (significant) deviation requiring prompt IRB reporting?

A subject's study visit occurred 2 days outside the allowed visit window
A required quality-of-life questionnaire was administered in a different order than specified
An ineligible subject was enrolled because inclusion criteria were not properly verified (Correct answer)
A laboratory sample was processed 30 minutes later than the protocol specified

Correct answer: An ineligible subject was enrolled because inclusion criteria were not properly verified

Enrolling an ineligible subject directly violates inclusion/exclusion criteria, potentially affecting subject safety and data integrity, making it a major deviation requiring prompt IRB notification.

Question 12: When can consent requirements be waived?

Waived for Phase I
In specific emergency research situations (21 CFR 50.24) when consent is not feasible for life-threatening conditions (Correct answer)
Any investigator can waive
Never

Correct answer: In specific emergency research situations (21 CFR 50.24) when consent is not feasible for life-threatening conditions

Under 21 CFR 50.24, consent may be waived for emergency research with life-threatening conditions when consent is not feasible.

Question 13: During source data verification (SDV), a CRA finds that the hemoglobin value recorded in the case report form (CRF) does not match the laboratory report in the medical record. What is the correct course of action?

Delete the laboratory result from the source document to eliminate the discrepancy
Ask the site staff to make a corrected entry in the CRF following GCP guidelines — crossing out the error, entering the correct value, dating, and initialing — and document the discrepancy in the monitoring visit report (Correct answer)
Accept the CRF value as correct since it was entered by the investigator
Correct the CRF entry directly without documentation

Correct answer: Ask the site staff to make a corrected entry in the CRF following GCP guidelines — crossing out the error, entering the correct value, dating, and initialing — and document the discrepancy in the monitoring visit report

GCP requires that any CRF correction be made by striking through the error, writing the correct value, and having the person making the correction date and initial it. The CRA must also document this discrepancy finding in the monitoring visit report.

Question 14: In a crossover design, which statement is true?

Each subject receives the treatments being compared in sequence, often with a washout period in between (Correct answer)
Each subject receives only one treatment for the whole study
Subjects are never randomized
It is used mainly for acute, curable conditions

Correct answer: Each subject receives the treatments being compared in sequence, often with a washout period in between

In a crossover trial, each subject receives the treatments being compared in sequence, so each subject acts as their own control. A washout period reduces carryover effects. This design works best for stable, chronic conditions.

Question 15: What authority does an IRB have when it determines that unanticipated problems pose serious risks to participants or others?

The IRB can issue a warning letter but must allow the study to continue until federal review
The IRB may only recommend modifications; only the sponsor can halt the study
The IRB must defer to the FDA before taking any enforcement action
The IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with its requirements (Correct answer)

Correct answer: The IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with its requirements

Per 45 CFR 46.113, an IRB has the authority to suspend or terminate approval of research that is not being conducted in accordance with the IRB's requirements or that has been associated with unexpected serious harm to participants. This is a core institutional safeguard.

Question 16: Which statement about electronic signatures under 21 CFR Part 11 is correct?

A typed name at the bottom of an email qualifies as a compliant electronic signature
Electronic signatures must be unique to the individual and require at least two distinct identification components for first use (Correct answer)
Any digital image of a handwritten signature complies with Part 11 requirements
Electronic signatures are only valid if witnessed by a third party

Correct answer: Electronic signatures must be unique to the individual and require at least two distinct identification components for first use

Part 11 requires electronic signatures to be unique to one individual and executed with at least two distinct components (e.g., user ID and password) upon first signing.

Question 17: What is a person or an organization (commercial, academic, or other) contracted by the sponsor of a clinical trial to perform one or more trial-related duty and function?

CRO - Contracted Research Organization (Correct answer)
CRO - Contracted Research Operations
CRO - Center for Research Operations
CRO - Clinical Research Organization

Correct answer: CRO - Contracted Research Organization

A CRO, or Contracted Research Organization, is an entity hired by a sponsor to manage and perform various tasks related to a clinical trial. These tasks can include study design, monitoring, data management, and regulatory affairs. The term 'Contracted Research Organization' accurately reflects its role as an external, specialized service provider for clinical research.

Question 18: Which federal regulation primarily governs the protection of human subjects in research conducted or supported by the U.S. Department of Health and Human Services?

21 CFR Part 11
21 CFR Part 312
45 CFR Part 164
45 CFR Part 46 (Correct answer)

Correct answer: 45 CFR Part 46

45 CFR Part 46, also known as the Common Rule, is the primary federal regulation protecting human research subjects under HHS.

Question 19: In adverse event causality assessment, what does a 'probable' relationship between an investigational product and an adverse event indicate?

The investigational product is the sole confirmed cause of the adverse event
The causal relationship cannot be evaluated due to insufficient information
A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge (Correct answer)
No plausible biological relationship exists between the drug and the event

Correct answer: A reasonable causal relationship exists and alternative explanations are unlikely, with the event improving on dechallenge

'Probable' causality means there is a plausible time relationship, alternative explanations are unlikely, and the event typically improves on dechallenge (withdrawal of the drug). It suggests a likely connection but does not reach the certainty of 'definite,' which also requires positive rechallenge or definitive confirmation.

Question 20: The Nuremberg Code was developed primarily in response to which historical event?

Nazi medical experiments conducted on prisoners during World War II (Correct answer)
Thalidomide birth defect crisis of the 1950s–60s
Willowbrook hepatitis studies involving children with intellectual disabilities
Unethical syphilis experiments on African American men in Alabama

Correct answer: Nazi medical experiments conducted on prisoners during World War II

The Nuremberg Code (1947) was established after the Nuremberg Doctors' Trial revealed the atrocities of Nazi medical experimentation.

Question 21: What is an IRB audit?

Review of participant records
Assessment of drug quality
Financial audit
A systematic examination of IRB operations, procedures, and records for regulatory compliance (Correct answer)

Correct answer: A systematic examination of IRB operations, procedures, and records for regulatory compliance

An IRB audit examines operations, decision-making, record-keeping, and compliance with 21 CFR 56 and 45 CFR 46.

Question 22: An investigator wants to waive the requirement for signed informed consent documentation. Which regulation governs this waiver?

45 CFR 46.111(a)
45 CFR 46.117(c) (Correct answer)
21 CFR 50.25(a)
21 CFR 50.27(c)

Correct answer: 45 CFR 46.117(c)

45 CFR 46.117(c) permits the IRB to waive the requirement for a signed consent form under specific conditions.

Question 23: A subject who signed consent 3 months ago now asks for a copy of their consent form. What must the investigator do?

Provide the subject with a copy; subjects are entitled to a copy of the signed consent document (Correct answer)
Only provide a copy if the IRB approves the request
Refer the subject to the sponsor for a copy
Decline because the consent was already signed

Correct answer: Provide the subject with a copy; subjects are entitled to a copy of the signed consent document

21 CFR 50.27 and ethical principles require that subjects receive a copy of the signed consent form, and this right persists throughout the study.

Question 24: Which condition must be met for an IRB to approve a waiver of informed consent for research under 45 CFR 46.116(f)?

The research must involve only healthy volunteers
The sponsor must request the waiver in writing
The research could not practicably be carried out without the waiver (Correct answer)
The study must be double-blinded

Correct answer: The research could not practicably be carried out without the waiver

One key criterion for a consent waiver is that the research could not practicably be carried out without the waiver of informed consent.

Question 25: What is the purpose of a drug accountability log in a clinical trial?

To track subject adverse events related to the study drug
To summarize IP costs for budget reconciliation
To record all IP received, dispensed, returned, and destroyed at the site (Correct answer)
To document pharmacy staff credentials

Correct answer: To record all IP received, dispensed, returned, and destroyed at the site

The drug accountability log provides a complete inventory record of IP movement, enabling reconciliation and regulatory compliance verification.

Question 26: What is the difference between an adverse event (AE) and an adverse drug reaction (ADR)?

No difference
An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship (Correct answer)
An AE only occurs during treatment
An ADR is less serious

Correct answer: An AE is any untoward occurrence regardless of causality; an ADR implies a causal relationship

An AE is any untoward medical occurrence regardless of causal relationship; an ADR implies at least a reasonable possibility of causal relationship.

Question 27: A participant signed an informed consent form for a clinical trial a year ago. The protocol has now been amended to include a new, optional blood draw for future genetic research. Which of the following actions is required?

Obtain re-consent from all active participants using an IRB-approved revised consent form that includes the new optional procedure. (Correct answer)
Verbally inform the participant of the optional blood draw at their next visit and document their agreement in the progress notes.
Send a letter to all participants informing them of the new optional procedure.
No action is needed as the participant already consented to the main trial.

Correct answer: Obtain re-consent from all active participants using an IRB-approved revised consent form that includes the new optional procedure.

When a protocol is amended with new information or procedures that might affect a participant's willingness to continue, such as an optional genetic research component, re-consent is required. The investigator must use a revised, IRB-approved informed consent form to explain the changes and document the participant's decision to agree to the new procedures or continue under the terms of the original consent.

Question 28: Which of the following BEST defines a protocol deviation in a clinical trial?

Any change to the protocol that is approved by the sponsor in advance
An unplanned departure from the procedures described in the approved protocol (Correct answer)
A formal amendment to the protocol submitted to the IRB
A sponsor-initiated modification to study eligibility criteria

Correct answer: An unplanned departure from the procedures described in the approved protocol

A protocol deviation is an unplanned, unintentional departure from the approved protocol procedures that occurs during the conduct of a study.

Question 29: Which FDA regulation specifically governs the obligations of clinical investigators in conducting clinical trials?

21 CFR Part 54
21 CFR Part 312 Subpart D (Correct answer)
21 CFR Part 314
21 CFR Part 50

Correct answer: 21 CFR Part 312 Subpart D

21 CFR Part 312 Subpart D (Responsibilities of Sponsors and Investigators) outlines the specific obligations of clinical investigators under FDA regulations.

Question 30: When does the Common Rule (45 CFR 46 Subpart A) apply to research?

When research is conducted or supported by a federal department or agency (Correct answer)
When more than 100 subjects are enrolled
Only to privately funded research
Only to FDA-regulated research

Correct answer: When research is conducted or supported by a federal department or agency

The Common Rule applies to research that is conducted or supported by any federal department or agency that has adopted it.

Question 31: According to ICH E6(R2), what is the required timeframe for an investigator to report an unexpected serious adverse event (SAE) to the sponsor?

Within 5 working days, as defined by local regulations
Within 48 hours, with a follow-up report within 15 days
Within 7 calendar days of becoming aware of the event
Within 24 hours of becoming aware of the event, followed by a written report within 8 days (Correct answer)

Correct answer: Within 24 hours of becoming aware of the event, followed by a written report within 8 days

ICH E6(R2) Section 4.11 requires that all serious adverse events be reported immediately to the sponsor, except those identified in the protocol as not requiring immediate reporting. The standard expectation is immediate (within 24 hours) notification with a detailed written follow-up within 8 days.

Question 32: During an informed consent discussion for a complex oncology trial, the investigator notices the potential participant is nodding along but seems overwhelmed and is not asking any questions. What is the best practice for the investigator to ensure adequate understanding?

Provide the participant with a copy of the consent form and tell them to call later if they think of any questions.
Use a teach-back method, asking the participant to explain the study's purpose, risks, and procedures in their own words. (Correct answer)
Ask the participant, "Do you have any questions?" and if they say no, proceed with signing the form.
Document in the research record that the participant appeared to understand and agreed to participate.

Correct answer: Use a teach-back method, asking the participant to explain the study's purpose, risks, and procedures in their own words.

The informed consent process is more than a signature; it's about ensuring genuine comprehension. The teach-back method is an effective technique to assess and confirm a participant's understanding. It moves beyond simple yes/no questions and requires the participant to actively demonstrate their grasp of the key information, allowing the investigator to identify and clarify any areas of misunderstanding.

Question 33: Under 21 CFR Part 312, what is the minimum notice period a sponsor must provide to an investigator before conducting a routine site audit?

24 hours
5 business days
48 hours
No minimum notice is required by regulation (Correct answer)

Correct answer: No minimum notice is required by regulation

FDA regulations do not mandate a minimum advance notice period for sponsor audits; sponsors set their own notice policies per SOPs.

Question 34: If an investigator uses an investigational device on a subject without obtaining informed consent, such as in an emergency, when must the investigator report this to the sponsor and the IRB?

Within 24 hours
At the next continuing review
Within 10 working days
Within 5 working days after the use (Correct answer)

Correct answer: Within 5 working days after the use

21 CFR 812.150(a)(5) requires the investigator to report the use to the sponsor and the reviewing IRB within 5 working days after the use occurs.

Question 35: During a site audit, the investigator is asked to produce the original signed informed consent forms. These documents are most accurately categorized as:

IRB records that cannot be inspected by the sponsor
Sponsor-controlled documents only
Administrative records with no source document status
Essential documents and also source documents for consent data (Correct answer)

Correct answer: Essential documents and also source documents for consent data

Signed informed consent forms are both essential documents required by GCP and source documents capturing the date, time, and fact of subject consent.

Question 36: Unless FDA notifies the sponsor otherwise, when does an IDE for a significant risk device take effect?

60 days after FDA receives it
Immediately on submission
30 days after FDA receives it (Correct answer)
15 days after FDA receives it

Correct answer: 30 days after FDA receives it

Under 21 CFR 812.30(a), an IDE takes effect 30 days after FDA receives the application unless FDA notifies the sponsor that the investigation may not begin. This matches the 30-day wait for an IND.

Question 37: Which of the following is the best definition of a source document according to ICH GCP guidelines?

A form provided by the sponsor, either paper or electronic, designed to record all of the protocol-required information for a trial subject.
A report created by the monitor after a site visit that summarizes all findings and data discrepancies.
The final, signed clinical study report that is submitted to regulatory authorities for marketing approval.
Original documents, data, and records where trial information is first recorded, such as hospital records, lab notes, or subject diaries. (Correct answer)

Correct answer: Original documents, data, and records where trial information is first recorded, such as hospital records, lab notes, or subject diaries.

ICH GCP 1.52 defines source documents as the original records (and certified copies) of clinical findings, observations, or other activities in a trial. This is where the data is first recorded. A Case Report Form (CRF) is used to transcribe this data for the sponsor, but the original record itself is the source document.

Question 38: The Code of Federal Regulations that applies to Investigational New Drug Applications is..

21CFR11
21CFR812
21CFR312 (Correct answer)
45CFR46

Correct answer: 21CFR312

21 CFR Part 312 specifically governs 'Investigational New Drug Applications' (INDs). This regulation outlines the requirements for submitting an IND to the FDA, which is necessary before a new drug can be tested in human subjects. It details the information sponsors must provide regarding the drug's manufacturing, preclinical testing, and proposed clinical protocols to ensure subject safety.

Question 39: What is a placebo in clinical research?

The standard of care treatment
An inactive substance or treatment used as a comparator (Correct answer)
A type of adverse event
A higher dose of the investigational drug

Correct answer: An inactive substance or treatment used as a comparator

A placebo is an inactive substance designed to resemble the investigational product but contains no active therapeutic ingredients.

Question 40: Under which circumstance may an IRB grant a waiver of informed consent for research involving human subjects?

The research involves greater than minimal risk but the investigator prefers not to obtain consent
The research could not practicably be carried out without the waiver, involves minimal risk, and will not adversely affect subjects' rights or welfare (Correct answer)
The sponsor has determined that consent is unnecessary for operational efficiency
The IRB chair has sole authority to waive consent without full board review

Correct answer: The research could not practicably be carried out without the waiver, involves minimal risk, and will not adversely affect subjects' rights or welfare

Federal regulations (45 CFR 46.116) permit an IRB to waive or alter informed consent when the research involves no more than minimal risk, the waiver will not adversely affect subjects' rights and welfare, the research could not practicably be carried out without the waiver, and subjects are debriefed where appropriate.

Question 41: The 'Enduring' attribute added to ALCOA+ means that source data must be:

Submitted to the FDA within a defined timeframe
Stored in a way that it remains readable and accessible for the required retention period (Correct answer)
Reviewed by the sponsor at least annually
Backed up daily to a cloud server

Correct answer: Stored in a way that it remains readable and accessible for the required retention period

Enduring means data must be stored in durable formats that remain legible and retrievable throughout the required retention period.

Question 42: When assessing causality, a 'positive rechallenge' refers to:

A second investigator confirming the initial causality assessment
The AE recurring or worsening when the investigational drug is reintroduced after a dechallenge (Correct answer)
The AE resolving after stopping the drug
A regulatory authority confirming a causal link between drug and AE

Correct answer: The AE recurring or worsening when the investigational drug is reintroduced after a dechallenge

A positive rechallenge — where the AE reappears upon reintroduction of the drug — substantially strengthens evidence of a causal relationship.

Question 43: Which of the following best describes FDA's 'clinical hold' authority under 21 CFR 312.42?

A temporary suspension of IND review while FDA requests more information
An FDA order to delay or suspend a clinical investigation for safety or compliance reasons (Correct answer)
A request for additional preclinical data before IND approval
An order to pause subject enrollment pending safety review

Correct answer: An FDA order to delay or suspend a clinical investigation for safety or compliance reasons

A clinical hold under 21 CFR 312.42 is an FDA order to delay initiation or suspend an ongoing clinical investigation when safety or compliance concerns exist.

Question 44: An FDA inspector arrives unannounced at a clinical investigator's site. What should the site staff do first?

Contact the sponsor or CRO and ask the inspector to wait while notification is made (Correct answer)
Refuse entry until legal counsel is present
Immediately grant full access to all study files without notifying anyone
Begin shredding any documents that might reflect poorly on the site

Correct answer: Contact the sponsor or CRO and ask the inspector to wait while notification is made

Sites should notify the sponsor or CRO as quickly as possible when an FDA inspection occurs. The inspector can be politely asked to wait briefly while the principal investigator and sponsor are notified, which is standard industry practice and does not obstruct the inspection.

Question 45: A participant in a double-blinded trial presents to an outside emergency room with a life-threatening condition. The treating physician believes knowing the treatment assignment is critical for patient care. According to standard procedures, who holds the primary authority and mechanism to grant an emergency unblinding request?

The Sponsor or their designated representative (e.g., medical monitor). (Correct answer)
The Chairperson of the Institutional Review Board (IRB).
The Principal Investigator, who can unblind at their sole discretion.
The lead research pharmacist at the investigational site.

Correct answer: The Sponsor or their designated representative (e.g., medical monitor).

The sponsor holds the randomization code for the entire study and is responsible for establishing and maintaining the procedure for emergency unblinding. While the PI would facilitate the request, the formal process requires contacting the sponsor (or a 24/7 service designated by them) who can officially break the blind for a specific participant when it is medically necessary. This ensures the integrity of the overall study is protected while prioritizing subject safety.

Question 46: Under 21 CFR Part 11, which requirement applies to electronic records used as source documents?

They must be stored on FDA-approved servers only
They only require a system administrator password for access control
They must be printed and signed in wet ink within 24 hours
They must have audit trails that capture who made changes and when, and electronic signatures must be linked to the record (Correct answer)

Correct answer: They must have audit trails that capture who made changes and when, and electronic signatures must be linked to the record

21 CFR Part 11 mandates secure audit trails and electronic signatures that are permanently linked to the electronic record to ensure data integrity.

Question 47: A for-cause audit differs from a routine audit primarily in that it is:

Performed only at the end of a trial
Required after every serious adverse event
Conducted by the FDA rather than the sponsor
Triggered by a specific concern or complaint about site conduct (Correct answer)

Correct answer: Triggered by a specific concern or complaint about site conduct

For-cause audits are initiated in response to a specific signal such as data anomalies, whistleblower complaints, or unusually high enrollment rates.

Question 48: Which element is NOT required to be included in an ICH GCP-compliant informed consent document?

Name of the sponsor's Chief Medical Officer (Correct answer)
Statement that participation is voluntary
Description of foreseeable risks and discomforts
Expected duration of the subject's participation

Correct answer: Name of the sponsor's Chief Medical Officer

ICH E6 lists specific required consent elements and the sponsor CMO's name is not among them; what matters is contact information for questions about rights and the trial.

Question 49: A CAPA plan developed after an audit finding should include which of the following components?

Root cause analysis, corrective actions taken, preventive measures, and a timeline for completion (Correct answer)
A list of personnel who will be terminated due to the finding
A request to the FDA to waive the finding
Only a description of the problem identified

Correct answer: Root cause analysis, corrective actions taken, preventive measures, and a timeline for completion

An effective CAPA plan must address the root cause of the problem, describe immediate corrective actions to fix current issues, outline preventive actions to stop recurrence, and provide a realistic timeline for implementation and verification of effectiveness.

Question 50: Before or at the time of using electronic signatures, organizations must certify to the FDA that:

Their software is FDA-approved
Electronic signatures are intended to be the legally binding equivalent of handwritten signatures (Correct answer)
All records will also be kept on paper
Passwords are changed daily

Correct answer: Electronic signatures are intended to be the legally binding equivalent of handwritten signatures

Section 11.100(c) requires a certification, submitted on paper with a traditional handwritten signature, that the organization's electronic signatures are the legally binding equivalent of handwritten signatures.

Question 51: A non-biometric electronic signature must use at least:

One component, such as a password
Two distinct identification components, such as a user ID and a password (Correct answer)
A fingerprint scan
A handwritten signature scanned into the system

Correct answer: Two distinct identification components, such as a user ID and a password

Section 11.200(a) requires non-biometric e-signatures to use at least two distinct identification components, such as an ID code and a password.

Question 52: What is the primary purpose of IP reconciliation at a clinical site?

To confirm that the site's pharmacy license is current
To ensure that every unit of IP received can be accounted for through dispensing, return, or destruction records (Correct answer)
To calculate the cost of the study drug for reimbursement
To verify that the investigator's brochure matches the product label

Correct answer: To ensure that every unit of IP received can be accounted for through dispensing, return, or destruction records

IP reconciliation verifies that the sum of units dispensed, returned unused, and destroyed equals the total units received. A complete reconciliation with no unexplained discrepancies is required by regulations and sponsor audits to demonstrate that no IP was diverted or misused.

Question 53: Under 21 CFR Part 312.32, within how many calendar days must a sponsor report an unexpected fatal or life-threatening serious adverse event to the FDA?

7 calendar days (Correct answer)
45 calendar days
15 calendar days
30 calendar days

Correct answer: 7 calendar days

21 CFR 312.32(c)(2) requires sponsors to notify the FDA within 7 calendar days of receiving information about an unexpected serious adverse event that is fatal or life-threatening, reflecting the urgency of protecting trial participants.

Question 54: What is the purpose of a 'closeout' monitoring visit?

To transfer the master file to the FDA
To obtain final IRB approval for the study report
To enroll the last subject into the study
To ensure all trial activities are completed, documents are archived, and investigational product is reconciled (Correct answer)

Correct answer: To ensure all trial activities are completed, documents are archived, and investigational product is reconciled

A closeout visit confirms all data are clean, investigational product is accounted for, and the site can properly archive trial records.

Question 55: Under FDA regulations, a CRO that assumes sponsor obligations must do which of the following?

Ensure that any uncanceled obligations revert back to the sponsor (Correct answer)
File an amendment to the IND listing the CRO as co-sponsor
Submit a CRO registration to FDA before conducting any trial activities
Obtain approval from the IRB before assuming responsibilities

Correct answer: Ensure that any uncanceled obligations revert back to the sponsor

Per 21 CFR 312.52, when a sponsor transfers obligations to a CRO, any obligations not covered by the CRO agreement revert to the sponsor.

Question 56: What is the difference between efficacy and effectiveness in clinical research?

Efficacy is measured in Phase IV while effectiveness is in Phase I
There is no difference
Efficacy measures results under ideal conditions while effectiveness measures results in real-world conditions (Correct answer)
Efficacy refers to safety while effectiveness refers to dosing

Correct answer: Efficacy measures results under ideal conditions while effectiveness measures results in real-world conditions

Efficacy refers to how well a treatment works under ideal, controlled conditions, while effectiveness refers to how well it works in routine, real-world clinical practice.

Question 57: IND safety reports (15-day expedited reports) submitted to the FDA must also be forwarded to:

Only the sponsor's legal department
The NIH clinical trials registry
All participating investigators under the IND (Correct answer)
The IRB that approved the sponsor's master protocol only

Correct answer: All participating investigators under the IND

Under 21 CFR 312.32, sponsors must promptly distribute IND safety reports (SUSARs/expedited reports) to all investigators participating under the IND.

Question 58: What is the Declaration of Helsinki?

A guideline for manufacturing investigational drugs
A set of ethical principles for medical research involving human subjects (Correct answer)
A US federal regulation governing clinical trials
A pharmacovigilance reporting standard

Correct answer: A set of ethical principles for medical research involving human subjects

The Declaration of Helsinki is a statement of ethical principles developed by the World Medical Association to guide medical research involving human subjects.

Question 59: The Belmont Report established a framework of basic ethical principles for research involving human subjects. Which of the following are the three core principles identified in this report?

Informed Consent, Risk/Benefit Assessment, and Subject Selection
Safety, Efficacy, and Scientific Validity
Respect for Persons, Beneficence, and Justice (Correct answer)
Autonomy, Confidentiality, and Integrity

Correct answer: Respect for Persons, Beneficence, and Justice

The Belmont Report, published in 1979, identified three fundamental ethical principles for all human subjects research: Respect for Persons, Beneficence, and Justice. These principles form the foundation for the ethical conduct of clinical research in the United States.

Question 60: Which of the following best describes a 'suspected adverse reaction' in the context of IND safety reporting?

Any AE occurring after the first dose regardless of relationship
An AE that is listed in the Investigator's Brochure as expected
An AE that resolves without medical intervention
An AE for which there is a reasonable possibility of a causal relationship to the investigational drug (Correct answer)

Correct answer: An AE for which there is a reasonable possibility of a causal relationship to the investigational drug

A suspected adverse reaction is any AE for which there is a reasonable possibility that the investigational drug caused the event, based on available evidence and clinical judgment.

Question 61: A site receives IP with a label stating 'For Investigational Use Only — Not for Sale.' This labeling requirement is mandated by which regulation?

21 CFR Part 56
21 CFR Part 50
21 CFR Part 312.6 (Correct answer)
ICH E8

Correct answer: 21 CFR Part 312.6

21 CFR Part 312.6 requires that investigational new drug products bear labels stating 'Caution: New Drug—Limited by Federal (or United States) law to investigational use.'

Question 62: When a child is capable of understanding the nature of a research study but has not yet reached the age of majority, what must occur IN ADDITION to obtaining parental or guardian permission?

A court order must authorize the child's participation
The IRB must conduct a direct interview with the child
The child's assent must be obtained (Correct answer)
A second parent must co-sign the permission form

Correct answer: The child's assent must be obtained

When children are capable of understanding, their assent — their affirmative agreement to participate — must be obtained in addition to parental or guardian permission. The IRB determines the appropriate assent process based on the child's age, maturity, and psychological state.

Question 63: What is the significance of lot number documentation in drug accountability records?

It is used exclusively for billing purposes
It is optional information included only for commercial drugs
It enables traceability for quality investigations, recalls, or stability issues linked to specific manufacturing batches (Correct answer)
It is recorded only when IP fails stability testing

Correct answer: It enables traceability for quality investigations, recalls, or stability issues linked to specific manufacturing batches

Lot numbers link each dispensed unit to a specific manufacturing batch, enabling full traceability for safety investigations, recalls, and stability monitoring.

Question 64: Which of the following is a disclosure of financial interests form?

3500, Fda 3500
21 Cfr 312
Form 3454
FDA Form 3455 (Correct answer)

Correct answer: FDA Form 3455

FDA Form 3455 is the correct form for disclosing financial interests in clinical research. This form is mandated by 21 CFR Part 54 and requires clinical investigators to report any financial arrangements that could potentially influence the outcome of a study. Its use helps ensure transparency and mitigate conflicts of interest in clinical trials.

Question 65: Which of the following is NOT a required element on the label of an investigational product according to 21 CFR 312.6?

The protocol code or study number.
A statement such as 'Caution: New Drug—Limited by Federal (or United States) law to investigational use.'
The name or identification code of the drug.
The name and address of the Principal Investigator. (Correct answer)

Correct answer: The name and address of the Principal Investigator.

21 CFR 312.6 specifies the labeling requirements for an investigational new drug. It requires a statement indicating the product is for investigational use. While GCP guidelines often lead to the inclusion of the protocol number, drug identifier, and sponsor information, the regulation does not explicitly require the Principal Investigator's name and address to be on the immediate product label; the sponsor's name and address is the standard requirement.

Question 66: What is 21CFR50 Subpart D?

IRB Functions and Operations
Protection of Human Subjects
Additional Safeguards for Children in Clinical Investigations (Correct answer)
Records and Reports

Correct answer: Additional Safeguards for Children in Clinical Investigations

21 CFR Part 50 Subpart D specifically addresses 'Additional Safeguards for Children in Clinical Investigations.' This subpart outlines the specific requirements and protections that must be in place when children are involved as subjects in clinical research. It ensures that children, as a vulnerable population, are adequately protected and that their participation is ethically justified.

Question 67: The form ___ is used for investigational new drugs (or IND)

3500a
1572
1583
1571 (Correct answer)

Correct answer: 1571

FDA Form 1571, titled 'Investigational New Drug Application (IND) – Sponsor,' is the primary form used to submit an Investigational New Drug Application to the FDA. This form initiates the process for a sponsor to seek permission to test a new drug in human subjects. It serves as the cover sheet and summary for the comprehensive IND submission.

Question 68: Which of the following documents is the primary, comprehensive record used at a clinical site to track the investigational product from receipt to its final disposition?

The subject's individual case report forms.
The Investigational Product Accountability Log. (Correct answer)
The Investigator's Brochure.
The bill of lading from the shipping courier.

Correct answer: The Investigational Product Accountability Log.

The Investigational Product Accountability Log is the central and essential document specifically designed to track the entire lifecycle of the product at the site. It records dates, quantities, batch numbers, expiration dates, and details of every unit received, dispensed to subjects, returned by subjects, and ultimately returned to the sponsor or destroyed.

Question 69: Which additional attributes extend the basic ALCOA principles to 'ALCOA+' in clinical research source documentation?

Certified, Controlled, Encrypted, and Archived
Corrected, Centralized, Evaluated, and Approved
Complete, Consistent, Enduring, and Available (Correct answer)
Authenticated, Chronological, Comprehensive, and Electronic

Correct answer: Complete, Consistent, Enduring, and Available

ALCOA+ expands on the foundational ALCOA framework by adding Complete, Consistent, Enduring, and Available — attributes that ensure data is not only accurate at the moment of recording but remains intact, coherent across records, and accessible throughout the study lifecycle.

Question 70: During a routine on-site monitoring visit, a Clinical Research Associate (CRA) is responsible for all of the following activities EXCEPT:

Issuing an official FDA Form 483 for observed regulatory non-compliance. (Correct answer)
Verifying that informed consent was obtained prior to any study-specific procedures.
Comparing data in the source documents with the entries in the Case Report Forms (CRFs).
Checking the storage conditions and accountability of the investigational product.

Correct answer: Issuing an official FDA Form 483 for observed regulatory non-compliance.

Issuing a Form FDA 483, which lists inspectional observations, is a function reserved for an FDA inspector at the conclusion of a regulatory inspection. [16, 20] A CRA's role is to identify and help correct issues, but they do not have the regulatory authority to issue this form.

Question 71: A clinical trial is using a validated electronic system for participants to directly enter their daily symptom information via a smartphone app. This data is considered eSource. To be compliant with FDA regulations, this electronic system must primarily adhere to which of the following standards for electronic records and signatures?

ICH E6(R2)
45 CFR 46 (The Common Rule)
21 CFR Part 56
21 CFR Part 11 (Correct answer)

Correct answer: 21 CFR Part 11

21 CFR Part 11 is the FDA regulation that establishes the criteria under which electronic records and electronic signatures are considered trustworthy, reliable, and equivalent to paper records. It is critical for systems capturing eSource data in FDA-regulated trials, ensuring features like audit trails, system validation, and security are in place.

Question 72: When a U.S.-funded clinical trial is conducted in a developing country, the ethical standard for participant protections must be:

Only the local country's minimum legal requirements
Set by the local community leaders without external input
At least equivalent to the standards that would apply in the United States (Correct answer)
Determined solely by the international sponsor

Correct answer: At least equivalent to the standards that would apply in the United States

The Common Rule and ICH GCP require that research conducted abroad with U.S. funding afford protections equivalent to those required domestically.

Question 73: According to ICH E6, what is the primary responsibility of an Independent Ethics Committee (IEC)?

Approve the study budget and financial arrangements
Ensure trial sites have adequate resources
Safeguard the rights, safety, and well-being of trial subjects (Correct answer)
Verify the sponsor's regulatory submissions

Correct answer: Safeguard the rights, safety, and well-being of trial subjects

The IEC's primary mandate under ICH E6 is to protect the rights, safety, and well-being of trial subjects.

Question 74: Which document specifically tracks the movement of investigational product from the manufacturer to the investigator site?

Chain of Custody / Shipping manifest (Correct answer)
Investigator Brochure
Informed consent form
Protocol amendment

Correct answer: Chain of Custody / Shipping manifest

The chain of custody or shipping manifest documents the transfer of IP from origin to destination, ensuring accountability at every step.

Question 75: An investigator at a clinical trial site realizes that a study participant was inadvertently enrolled despite not meeting a key inclusion criterion. According to ICH GCP principles, what is the MOST appropriate immediate action for the investigator to take?

Continue the participant in the trial but exclude their data from the final analysis.
Wait for the next monitoring visit to discuss the issue with the Clinical Research Associate (CRA).
Take appropriate measures to protect the participant's safety and well-being, document the deviation, and report it to the sponsor and IRB/IEC as required. (Correct answer)
Inform the participant that they are being withdrawn from the study and document the event.

Correct answer: Take appropriate measures to protect the participant's safety and well-being, document the deviation, and report it to the sponsor and IRB/IEC as required.

ICH GCP emphasizes the paramount importance of protecting the rights, safety, and well-being of trial subjects. When a protocol deviation like this occurs, the investigator's first priority is the subject's safety. The investigator must then document the deviation and report it to the sponsor and the IRB/IEC according to their respective policies and regulatory requirements to ensure transparency and proper oversight.

Question 76: At what point in the research process must a subject's informed consent be obtained?

Within 48 hours after the initial study visit is completed
At the time of randomization into active or placebo arms
Before the first dose of investigational product is administered
Before any study-related procedures are performed, including screening procedures (Correct answer)

Correct answer: Before any study-related procedures are performed, including screening procedures

Informed consent must be obtained before any study-related procedures are performed — this includes screening activities such as blood draws or questionnaires conducted to determine eligibility. No research activity may begin until the subject has had adequate time to consider participation and has voluntarily signed the consent form.

Question 77: A local community in a low-income country has no access to the experimental treatment being tested in a trial conducted there. The Declaration of Helsinki requires that:

The study proceeds as long as local IRB approval is obtained
Participants be compensated financially in lieu of treatment access
Post-trial access to beneficial interventions for study participants and communities should be considered during the design phase (Correct answer)
A separate placebo-controlled arm must be added for local participants

Correct answer: Post-trial access to beneficial interventions for study participants and communities should be considered during the design phase

The Declaration of Helsinki (2013 revision) states that provisions for post-trial access to beneficial interventions should be addressed in the study protocol.

Question 78: What is the difference between a protocol deviation and a protocol violation?

Deviations require IRB reporting; violations do not
A deviation is any departure from the protocol; a violation is a departure that has a significant impact on subject safety or data integrity (Correct answer)
They are synonymous terms used interchangeably in GCP
A violation is minor; a deviation is major

Correct answer: A deviation is any departure from the protocol; a violation is a departure that has a significant impact on subject safety or data integrity

A protocol deviation is any departure from the protocol; when a deviation significantly impacts subject safety, rights, or data integrity, it is classified as a violation requiring expedited reporting.

Question 79: What are key differences between an NDA and a BLA?

BLA is faster
NDA covers devices
No difference
NDA is for drugs/small molecules; BLA is for biological products including vaccines and gene therapies (Correct answer)

Correct answer: NDA is for drugs/small molecules; BLA is for biological products including vaccines and gene therapies

NDA (21 CFR 314) is for drugs; BLA (42 USC 262) is for biological products.

Question 80: What is a source document agreement?

Participant consent for data access
Data sharing between sites
Site-hospital contract
A prospective agreement identifying which documents serve as source for each type of trial data (Correct answer)

Correct answer: A prospective agreement identifying which documents serve as source for each type of trial data

A prospective agreement identifying source documents for each data element, ensuring clarity during monitoring.

Question 81: An IEC must review and approve which of the following documents before a trial begins?

Investigator's CV only
Protocol, informed consent form, and subject recruitment materials (Correct answer)
Final clinical study report
Case report form templates only

Correct answer: Protocol, informed consent form, and subject recruitment materials

ICH E6 section 3.1 requires the IEC to review the protocol, consent forms, recruitment materials, and other subject-facing documents before trial initiation.

Question 82: Under ICH E6(R2), what is the primary purpose of an Institutional Review Board (IRB) or Independent Ethics Committee (IEC)?

To audit the sponsor's quality management system and approve the monitoring plan
To verify the financial disclosures of investigators and ensure there are no conflicts of interest
To safeguard the rights, safety, and well-being of all trial subjects by reviewing and providing ongoing oversight of the trial (Correct answer)
To approve the statistical analysis plan and validate the biostatistical methods used in the trial

Correct answer: To safeguard the rights, safety, and well-being of all trial subjects by reviewing and providing ongoing oversight of the trial

Per ICH E6(R2), the IRB/IEC exists to safeguard the rights, safety, and well-being of human subjects involved in a trial. It reviews protocols, informed consent documents, and other relevant information, and provides continuing oversight throughout the trial.

Question 83: What is therapeutic misconception?

The mistaken belief that all study aspects are for personal therapeutic benefit rather than science (Correct answer)
Deliberate deception
Medical error
Disagreement about efficacy

Correct answer: The mistaken belief that all study aspects are for personal therapeutic benefit rather than science

When participants fail to distinguish between research goals and clinical care, compromising truly informed consent.

Question 84: An FDA inspector concludes an inspection of a clinical site and issues a Form FDA 483 with three observations. What is the most critical next step for the Principal Investigator?

Appeal the findings to the Institutional Review Board (IRB).
Wait for the sponsor to handle all communication with the FDA.
Immediately stop all trial activities until the observations are resolved.
Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan. (Correct answer)

Correct answer: Submit a formal written response to the FDA, typically within 15 business days, detailing a corrective and preventive action (CAPA) plan.

Upon receiving a Form FDA 483, the investigator is expected to provide a timely written response to the FDA, generally within 15 business days. [18, 22] This response should address each observation and outline the site's plan for corrective and preventive actions. [18]

Question 85: A researcher modifies the study protocol to add a new data collection questionnaire. What must occur before implementing this change?

Notify the sponsor only
Inform participants verbally and document it in their records
Implement the change immediately and report it at the next continuing review
Obtain IRB approval of the amendment, then implement (Correct answer)

Correct answer: Obtain IRB approval of the amendment, then implement

Protocol amendments must be reviewed and approved by the IRB before implementation, except when necessary to eliminate immediate hazard.

Question 86: A research participant, who is a competent adult, initially consents to a long-term observational study. Two years into the study, the participant contacts the site to withdraw. Applying the principle of 'Respect for Persons,' what is the most appropriate action for the research team?

Honor the participant's decision to withdraw immediately without penalty or loss of benefits to which they are otherwise entitled. (Correct answer)
Inform the participant that they must provide a valid reason for withdrawal to be processed.
Continue using the participant's data collected up to the point of withdrawal but stop all future contact.
Persuade the participant to continue, explaining the value of their long-term data.

Correct answer: Honor the participant's decision to withdraw immediately without penalty or loss of benefits to which they are otherwise entitled.

The principle of Respect for Persons recognizes individual autonomy and the right to self-determination. A key application of this principle is that participation must be voluntary throughout the research, which includes the right to withdraw at any time without penalty or having to justify the decision.

Question 87: A sub-investigator joins the study after activation. What document must be updated immediately?

The IRB approval letter
The Delegation of Authority log (Correct answer)
The Investigator's Brochure
The protocol

Correct answer: The Delegation of Authority log

The Delegation of Authority (DOA) log must be updated to reflect any new personnel and the tasks they are delegated before they perform study activities.

Question 88: A sponsor is required by 21 CFR 312.32 to submit an IND safety report to the FDA and all participating investigators for which type of event?

Any adverse event that leads to a participant's withdrawal from the study.
Only for adverse events that are both fatal and definitively related to the investigational drug.
Any Serious Adverse Event (SAE) that occurs at any study site, regardless of causality.
A suspected adverse reaction that is both serious and unexpected. (Correct answer)

Correct answer: A suspected adverse reaction that is both serious and unexpected.

According to 21 CFR 312.32(c)(1), the sponsor must notify the FDA and all participating investigators of any suspected adverse reaction that is both serious and unexpected. This ensures all investigators are promptly informed of potential new risks, which may affect subject safety or require changes to the protocol or informed consent form.

Question 89: At the conclusion of a clinical trial, what is the required procedure for handling unused investigational product at the clinical site?

The unused product should be returned to the site's general pharmacy stock for dispensing.
The Principal Investigator may use the remaining product for compassionate use cases.
The site should destroy all unused product and notify the IRB of the destruction.
The site must follow the sponsor's instructions for the return or authorized destruction of the unused product. (Correct answer)

Correct answer: The site must follow the sponsor's instructions for the return or authorized destruction of the unused product.

The sponsor is the owner of the investigational product and is ultimately responsible for its final disposition. According to 21 CFR 312.59 and ICH GCP, the site must reconcile all investigational product and then follow the sponsor's specific written instructions for either returning the unused supply or destroying it on-site. All actions must be thoroughly documented in the accountability records.

Question 90: What is the IRB's role in privacy and confidentiality?

Only HIPAA
Solely investigator's concern
No role
Must ensure adequate provisions for protecting privacy and maintaining confidentiality of identifiable information (Correct answer)

Correct answer: Must ensure adequate provisions for protecting privacy and maintaining confidentiality of identifiable information

Per 21 CFR 56.111(a)(7), the IRB must determine adequate privacy and confidentiality provisions exist.

Question 91: What is the minimum number of IRB members?

5 (Correct answer)
3
6
10

Correct answer: 5

According to FDA regulations (21 CFR 56.107), an Institutional Review Board (IRB) must have at least five members. This minimum number ensures a diverse range of expertise and perspectives are present during the review of research protocols. A larger, diverse committee helps to provide a thorough and unbiased ethical and scientific review of studies involving human subjects.

Question 92: What is the role of pharmacovigilance during a clinical trial?

Manage the trial budget
Collect, assess, and report safety data throughout the trial lifecycle (Correct answer)
Manufacture the investigational product
Recruit participants

Correct answer: Collect, assess, and report safety data throughout the trial lifecycle

Pharmacovigilance is responsible for systematic collection, detection, assessment, monitoring, and prevention of adverse effects.

Question 93: A sponsor conducts a risk assessment and decides to centralize IP dispensing at a pharmacy hub rather than each site. This approach is best described as:

Centralized IP management, permissible when validated and compliant with local regulations (Correct answer)
A protocol amendment requiring full IRB re-review
An FDA prohibited practice under 21 CFR 312
A GCP violation because IP must be stored at the investigator site

Correct answer: Centralized IP management, permissible when validated and compliant with local regulations

Centralized dispensing models are permissible under GCP when properly validated, documented in the protocol, and compliant with applicable pharmacy and regulatory requirements.

Question 94: Which of the following is a primary responsibility of an Institutional Review Board (IRB) as defined by FDA regulations?

To approve or disapprove research and ensure the protection of the rights and welfare of human subjects. (Correct answer)
To negotiate the clinical trial agreement and budget with the sponsor.
To monitor the investigational product's manufacturing process for quality control.
To ensure the scientific validity and design of the research protocol.

Correct answer: To approve or disapprove research and ensure the protection of the rights and welfare of human subjects.

FDA regulations (21 CFR Part 56) establish that the primary purpose and authority of an IRB is to review, approve, require modifications to, or disapprove biomedical research involving human subjects. This role is critical to protect the rights, safety, and welfare of the participants.

Question 95: What is the main purpose of randomization in a clinical trial?

To remove the need for a control group
To make enrollment faster
To ensure every subject gets the active drug
To reduce selection bias and balance known and unknown confounders between groups (Correct answer)

Correct answer: To reduce selection bias and balance known and unknown confounders between groups

Random assignment prevents investigators from choosing who gets which treatment and tends to balance baseline characteristics across groups. This supports valid comparisons.

Question 96: When a sponsor unblocks treatment assignment to assess causality for an SAE, who should ideally remain blinded to preserve trial integrity?

The sponsor's pharmacovigilance safety team
Investigators and study site staff not involved in medical management (Correct answer)
The institutional review board reviewing the protocol
The regulatory authority receiving the report

Correct answer: Investigators and study site staff not involved in medical management

To protect trial integrity and minimize bias, investigators and staff not involved in direct medical management of the SAE should remain blinded whenever possible.

Question 97: During Source Data Verification (SDV), what specific comparison does the CRA perform?

The site's standard operating procedures against current sponsor guidelines
Adverse event narratives against published drug safety databases
Data recorded in the Case Report Form against the original source documents at the investigative site (Correct answer)
Protocol eligibility criteria against the subject's signed informed consent form

Correct answer: Data recorded in the Case Report Form against the original source documents at the investigative site

SDV requires the CRA to compare data entered in the CRF directly against the original source documents to confirm that transcription was accurate, complete, and unaltered. This process is the primary mechanism for detecting data entry errors and unauthorized changes.

Question 98: What is the role of a Federalwide Assurance (FWA) in human subjects research?

It replaces the need for individual IRB approval of protocols
It is required only for international research sites
It is a binding commitment made by an institution to comply with the Common Rule for HHS-supported research (Correct answer)
It is a grant application submitted to NIH for research funding

Correct answer: It is a binding commitment made by an institution to comply with the Common Rule for HHS-supported research

An FWA is a formal agreement between an institution and OHRP in which the institution commits to comply with 45 CFR 46 for all HHS-conducted or -supported research.

Question 99: What is the primary distinction between a sponsor audit and an FDA inspection of a clinical trial site?

Audits are mandatory by law; inspections are voluntary quality checks
Audits are conducted by the sponsor or a third party to assess compliance; inspections are conducted by regulatory authorities with legal enforcement power (Correct answer)
Inspections are conducted by the IRB; audits are conducted by the FDA
There is no meaningful difference — both result in FDA warning letters if issues are found

Correct answer: Audits are conducted by the sponsor or a third party to assess compliance; inspections are conducted by regulatory authorities with legal enforcement power

A sponsor audit is an internal quality assurance activity without regulatory enforcement authority, while an FDA inspection is a government activity that can result in regulatory actions including warning letters, clinical holds, or import alerts.

Question 100: How should an investigator prepare for a regulatory inspection?

Destroy documents with errors
Only prepare the PI
Refuse access
Ensure documents are organized, complete, and accessible; review compliance and address known issues (Correct answer)

Correct answer: Ensure documents are organized, complete, and accessible; review compliance and address known issues

Preparation includes organizing documents, ensuring staff readiness, reviewing compliance, and addressing known issues.

Question 101: What information must be included in an expedited safety report?

Patient identification, event description, suspect drug information, reporter information, and causality assessment (Correct answer)
Just the MedWatch form number
Only the participant's name
Only drug name and batch number

Correct answer: Patient identification, event description, suspect drug information, reporter information, and causality assessment

Reports must include patient identification, detailed event description, suspect drug information, reporter details, and causality assessment.

Question 102: Under 21 CFR Part 312, which IND application type is used when a sponsor wants to conduct a clinical investigation using a legally marketed drug for a new indication?

Treatment IND
Investigator IND (Correct answer)
Emergency IND
Research IND

Correct answer: Investigator IND

An Investigator IND is submitted when a physician-investigator initiates and conducts a study using a marketed drug for a new indication not on the label.

Question 103: According to FDA regulations (21 CFR 312.32), which of the following outcomes makes an adverse event classified as 'serious'?

Results in persistent or significant disability or incapacity (Correct answer)
Causes mild nausea lasting more than 24 hours
Requires an unscheduled outpatient clinic visit
Causes temporary fatigue or lethargy

Correct answer: Results in persistent or significant disability or incapacity

An SAE is one that results in death, is life-threatening, requires inpatient hospitalization, causes persistent or significant disability, is a congenital anomaly, or is medically significant.

Question 104: Which federal office is responsible for oversight of the protection of human research subjects in HHS-supported research?

Office for Human Research Protections (OHRP) (Correct answer)
National Institutes of Health (NIH) Office of Research Integrity
Centers for Medicare and Medicaid Services (CMS)
FDA Center for Biologics Evaluation and Research (CBER)

Correct answer: Office for Human Research Protections (OHRP)

The Office for Human Research Protections (OHRP) provides oversight, guidance, and enforcement for HHS-conducted or -supported human subjects research under 45 CFR 46.

Question 105: An investigator must report a serious adverse event (SAE) to the sponsor within what timeframe per ICH E6 GCP guidelines?

Within 7 calendar days of awareness
Immediately upon occurrence
Within 15 calendar days of occurrence
Within 24 hours of awareness (Correct answer)

Correct answer: Within 24 hours of awareness

ICH E6 requires investigators to report SAEs to the sponsor promptly, typically within 24 hours of first awareness of the event.

Question 106: A clinical trial protocol is amended to include a new secondary objective and an additional blood draw at Visit 3. According to ICH GCP, which of the following essential documents must be updated, approved by the IRB/IEC, and implemented by the site BEFORE the changes are enacted for any new or existing participants?

The Financial Disclosure Forms and the clinical trial agreement with the sponsor.
The signed protocol, the informed consent form, and any other relevant written information for subjects. (Correct answer)
The Delegation of Authority Log and the site's Standard Operating Procedures (SOPs).
The Investigator's Brochure and FDA Form 1572.

Correct answer: The signed protocol, the informed consent form, and any other relevant written information for subjects.

ICH GCP E6(R2) requires that any amendment to the protocol that affects the conduct of the trial or increases risk to subjects must be documented. A change in objectives and procedures necessitates updating the protocol itself and, crucially, the informed consent form (ICF) to ensure subjects are aware of the new procedures and can provide consent. These revised documents must be submitted to and approved by the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) before implementation.

Question 107: A subject experiences a serious unexpected adverse drug reaction. How should this affect the informed consent document?

The site can verbally inform subjects without updating the written consent
The sponsor absorbs the risk and subjects need not be informed
The ICF must be updated and re-consented with enrolled subjects if the new risk is relevant to their participation (Correct answer)
No change is needed unless the FDA requires it

Correct answer: The ICF must be updated and re-consented with enrolled subjects if the new risk is relevant to their participation

When new safety information emerges that may affect a subject's willingness to continue, the ICF must be updated and subjects must be re-consented in accordance with GCP.

Question 108: Under 21 CFR 312.32, a 'life-threatening adverse drug experience' is defined as one in which:

The subject required more than 24 hours of inpatient hospitalization
The event caused significant permanent disability
The event required a surgical intervention to resolve
The subject was at immediate risk of death at the time of the adverse event (Correct answer)

Correct answer: The subject was at immediate risk of death at the time of the adverse event

A life-threatening adverse drug experience is one where the subject was at immediate risk of dying at the time of the event — not one that hypothetically could have caused death.

Question 109: Under ICH E6(R2), how frequently must the Investigator's Brochure (IB) be reviewed and updated?

At least once per year, or more often if clinically significant new information emerges (Correct answer)
Upon every protocol amendment that changes the primary endpoint
Every six months, regardless of whether new safety data are available
Only at the end of each study phase (e.g., Phase I to Phase II transition)

Correct answer: At least once per year, or more often if clinically significant new information emerges

ICH E6(R2) requires the IB to be reviewed at least annually; if new information that significantly affects subject safety or trial conduct becomes available, an updated IB must be issued sooner. The annual minimum ensures investigators have current benefit–risk information, independent of protocol amendments or phase transitions.

Question 110: How often must a continuing IEC review occur at minimum under ICH GCP guidelines?

At least once per year (Correct answer)
Every 6 months
Only when protocol amendments are submitted
Every 3 months

Correct answer: At least once per year

ICH E6 requires that the IEC conduct continuing review of each ongoing trial at least once per year.

Question 111: A subject in a blinded trial is hospitalized, and the treating physician requests the subject's treatment assignment for clinical management. The PI should:

Follow the protocol's emergency unblinding procedure and document the unblinding event (Correct answer)
Provide the information verbally without documentation
Deny the request to protect trial integrity
Ask the sponsor's statistician for the randomization code

Correct answer: Follow the protocol's emergency unblinding procedure and document the unblinding event

Emergency unblinding must follow the protocol-defined procedure, be documented in source records and the subject's file, and typically be reported to the sponsor promptly.

Question 112: Risk-based monitoring (RBM) approaches may use targeted SDV instead of 100% SDV. What does targeted SDV prioritize?

Checking all financial records before verifying clinical data
Verifying only the last CRF page of each subject
Reviewing only safety reports and adverse event data
Focusing verification efforts on critical data fields and higher-risk sites based on data signals and risk assessment (Correct answer)

Correct answer: Focusing verification efforts on critical data fields and higher-risk sites based on data signals and risk assessment

Targeted SDV concentrates monitoring resources on the most critical data elements and higher-risk areas identified through ongoing risk assessment.

Question 113: Which type of IRB review is appropriate for research involving no more than minimal risk that fits specific federally defined categories?

Continuing review
Exempt review
Expedited review (Correct answer)
Full board review

Correct answer: Expedited review

Expedited review is used for research posing no more than minimal risk that falls within one of the nine federally designated categories.

Question 114: Which of the following best describes the role of a 'witness' to the informed consent process under FDA regulations?

The witness makes the consent decision for the subject
The witness reviews the consent form for scientific accuracy
The witness must be a licensed physician
The witness attests that the consent was explained to the subject and that the subject appeared to understand and voluntarily agreed (Correct answer)

Correct answer: The witness attests that the consent was explained to the subject and that the subject appeared to understand and voluntarily agreed

A witness attests to the authenticity of the consent process, confirming the subject received the information, understood it, and signed voluntarily.

Question 115: When a sponsor auditor discovers that a site has been enrolling subjects who do not meet key inclusion criteria, what is the MOST appropriate immediate action?

Remove all non-compliant subjects from the dataset without documentation
Terminate the trial immediately at that site
Notify the FDA before informing the investigator
Document the findings and issue a corrective action plan requiring the PI to review all enrolled subjects (Correct answer)

Correct answer: Document the findings and issue a corrective action plan requiring the PI to review all enrolled subjects

The auditor should document findings thoroughly and work with the site through a CAPA process, which includes the PI reviewing all enrolled subjects to assess impact.

Question 116: What is the PRIMARY distinction between a protocol deviation and a protocol violation?

Violations involve unapproved drug doses; deviations involve missed visits only
Violations are intentional departures while deviations are unintentional
Deviations require FDA reporting while violations are only reported to the IRB
A violation is a deviation that significantly affects subject safety or data integrity (Correct answer)

Correct answer: A violation is a deviation that significantly affects subject safety or data integrity

While usage varies by organization, a protocol violation is generally considered a deviation that significantly affects subject rights, safety, or the integrity of study data.

Question 117: How long must an IRB retain records of research activities, including minutes of convened meetings, under federal regulations?

Five years from the date of initial IRB approval
At least three years after completion of the research (Correct answer)
One year after study completion
Indefinitely, with no minimum retention period specified

Correct answer: At least three years after completion of the research

45 CFR 46.115(b) requires that IRB records, including minutes, membership rosters, and study files, be retained for at least three years after completion of the research. This ensures accountability and the ability to reconstruct IRB decisions during audits or investigations.

Question 118: An IRB reviews a new research protocol and determines that the risks to subjects outweigh the potential benefits. According to 21 CFR 56.109, what is the IRB's authority in this situation?

The IRB can only recommend changes but cannot stop the research from proceeding.
The IRB must approve the research if the sponsor provides additional funding for subject safety monitoring.
The IRB can approve the research on a probationary basis for 30 days.
The IRB can disapprove the research, preventing the investigator from conducting it at the institution. (Correct answer)

Correct answer: The IRB can disapprove the research, preventing the investigator from conducting it at the institution.

According to 21 CFR 56.109(a), an IRB has the authority to approve, require modifications in (to secure approval), or disapprove all research activities covered by the regulations. If the IRB determines the risks are not justified, it has the full authority to disapprove the study, and this decision is binding for the institution.

Question 119: Which scenario represents a violation of the 'Attributable' ALCOA principle?

A PI dates and signs the protocol signature page
A CRC documents their own initials on a delegated task
A nurse signs their initials next to a recorded vital sign
A data entry clerk enters data under another staff member's login credentials (Correct answer)

Correct answer: A data entry clerk enters data under another staff member's login credentials

Using another person's login credentials violates attributability because the data cannot be traced to the person who actually performed or recorded it.

Question 120: When is direct data entry (DDE) into an EDC system considered acceptable as source data?

Only when paper source documents have been lost
When the sponsor provides written approval for each individual entry
When the site has documented procedures establishing the EDC as the source and no prior paper record was created (Correct answer)
Only for non-safety data points

Correct answer: When the site has documented procedures establishing the EDC as the source and no prior paper record was created

DDE into EDC is acceptable as source when the site's SOPs designate the EDC as the source and data is entered contemporaneously without a prior paper record.

Question 121: Which ALCOA principle requires that data be recorded at the time the observation is made?

Accurate
Contemporaneous (Correct answer)
Original
Legible

Correct answer: Contemporaneous

Contemporaneous means data must be recorded at the time the observation occurs, not reconstructed later from memory.

Question 122: FDA Form 1572 (Statement of Investigator) legally binds an investigator to which of the following commitments?

Providing financial disclosure for all study-related payments received from the sponsor
Conducting the study in accordance with the protocol and applicable regulations, and allowing FDA inspections (Correct answer)
Certifying that all subjects have provided written informed consent before data analysis begins
Submitting annual IND progress reports to the FDA on behalf of the sponsor

Correct answer: Conducting the study in accordance with the protocol and applicable regulations, and allowing FDA inspections

FDA Form 1572 is a regulatory commitment by the principal investigator to conduct the trial per the protocol and applicable regulations (21 CFR Parts 312/50/54), maintain adequate records, and permit FDA access to those records. It is not an annual report form, a financial disclosure form, or a post-enrollment certification.

Question 123: What is the significance of FDA Form 3674?

Certifies that trial information has been or will be submitted to ClinicalTrials.gov (Correct answer)
Manufacturing certification
Investigator qualifications
Certifies drug safety

Correct answer: Certifies that trial information has been or will be submitted to ClinicalTrials.gov

Form 3674 certifies compliance with ClinicalTrials.gov requirements as mandated by FDAAA Section 801.

Question 124: According to FDA regulations at 21 CFR 312.62, how long must an investigator retain records of protocol deviations for drugs studied under an IND?

5 years after the last subject visit
2 years after the study is completed or discontinued, or 2 years after FDA approval (Correct answer)
1 year after study completion
7 years after the last enrolled subject completes the study

Correct answer: 2 years after the study is completed or discontinued, or 2 years after FDA approval

21 CFR 312.62(c) requires investigators to retain records for 2 years following the date a marketing application is approved or 2 years after the investigation is discontinued.

Question 125: Under ICH E6(R2), which of the following is considered an essential document that should be in the Trial Master File (TMF) before the clinical phase of the trial begins?

Signed informed consent forms collected from the first three enrolled subjects
The signed investigator protocol agreement and CV of the principal investigator (Correct answer)
Completed case report forms (CRFs) for all enrolled subjects
Final clinical study report submitted to the regulatory authority

Correct answer: The signed investigator protocol agreement and CV of the principal investigator

ICH E6(R2) Section 8.2 lists essential documents that should be available before the clinical phase begins. These include the signed protocol agreement and the investigator's current CV, which demonstrate the investigator's qualifications and their formal commitment to the protocol.

Question 126: How does risk-based data management differ from traditional?

Focuses quality control on critical data elements; traditional applies uniform controls to all data (Correct answer)
Traditional always superior
Means less data collection
No difference

Correct answer: Focuses quality control on critical data elements; traditional applies uniform controls to all data

Risk-based prioritizes critical data; traditional applies the same level uniformly.

Question 127: In the context of clinical trial safety reporting, which of the following best defines an 'unexpected' adverse reaction?

A serious adverse event that occurs with a greater frequency than previously reported.
Any adverse reaction that results in a subject requiring an unscheduled hospital visit.
An adverse event that is not listed in the clinical trial protocol as a potential risk.
An adverse reaction, the nature or severity of which is not consistent with the applicable product information, such as the Investigator's Brochure. (Correct answer)

Correct answer: An adverse reaction, the nature or severity of which is not consistent with the applicable product information, such as the Investigator's Brochure.

The standard regulatory definition from both ICH E2A and 21 CFR 312.32(a) defines an 'unexpected' adverse reaction as one where the nature or severity is not consistent with the current product information, which for an investigational product is the Investigator's Brochure.

Question 128: Why must site-specific normal laboratory ranges (reference ranges) be collected and maintained in the Trial Master File?

They allow the sponsor to convert local units to SI units in the clinical database
They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events (Correct answer)
They fulfill the IRB's annual continuing-review data submission requirement
They replace the need for a central laboratory manual when local labs are used

Correct answer: They enable accurate determination of whether laboratory results are clinically notable or constitute potential adverse events

Site-specific normal laboratory ranges are essential for contextualizing subject lab values: without knowing the local lab's reference intervals, neither investigators nor monitors can reliably classify a result as normal, abnormal-not-clinically-significant, or an adverse event. They do not replace lab manuals, serve unit conversion, or satisfy IRB reporting requirements.

Question 129: Which document must accompany each shipment of investigational product received at a clinical site?

A shipping manifest or drug receipt log signed by the investigator (Correct answer)
The site's IRB approval letter
The sponsor's financial disclosure form
A packing slip verified by the site's billing department

Correct answer: A shipping manifest or drug receipt log signed by the investigator

Every IP shipment must be documented with a drug receipt log or shipping manifest that captures quantity received, lot number, expiration date, and storage condition on arrival. This record is signed by an authorized site representative, typically the investigator or designated staff, to establish the chain of custody.

Question 130: Which document provides comprehensive information about the investigational product to the investigator?

The informed consent form
The monitoring plan
The investigator's brochure (Correct answer)
The case report form

Correct answer: The investigator's brochure

The Investigator's Brochure (IB) contains all relevant clinical and nonclinical data about the investigational product needed by investigators.

SOCRA CCRP — Certified Clinical Research Professional

The SOCRA CCRP exam is a 130-question certification assessment for clinical research professionals, covering U.S. federal regulations, ICH Good Clinical Practice guidelines, and ethical principles across the full clinical trial lifecycle.

130

Questions

240 min

Time Limit

71%

To Pass

Checking for saved progress...

Exam Rules

You can skip questions and return to them later
Flag questions for review before submitting
No feedback shown until you submit the entire exam
Unanswered questions count as wrong — answer everything
10 pretest questions are mixed in and don't affect your score
Timer auto-submits when time runs out
Your progress is auto-saved every 30 seconds

These practice questions were written with AI tools. They are not real exam questions. Exam facts are checked against the official sources listed below. Not reviewed by a subject-matter expert. Editorial policy

Sources & references

Exam facts on this page (fees, format, dates, passing scores) are checked against these official sources; the date is our last check. Editorial policy

socra.org — Renewal, score validity, retake fee, retake policy, score release, test delivery, registration deadline, test dates, time limit, exam format · verified Oct 2026